Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Studie zu ASP3082 bei Erwachsenen mit zuvor behandelten soliden Tumoren

13. Oktober 2026 aktualisiert von: Astellas Pharma Inc

Eine Phase-1-Studie zu ASP3082 bei Teilnehmern mit zuvor behandelten lokal fortgeschrittenen oder metastasierten Malignomen solider Tumore mit KRAS G12D-Mutation

This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP3082. The study aims to check how safe and well-tolerated ASP3082 is for people with advanced solid tumors that have a specific mutation called KRAS G12D.

This study will be in 2 parts.

In Part 1, different small groups of people will receive lower to higher doses of ASP3082 by itself, or together with cetuximab. Any medical problems will be recorded at each dose. This is done to find suitable doses of ASP3082, by itself or together with cetuximab, to use in Part 2 of the study. The first group will receive the lowest dose of ASP3082. A medical expert panel will check the results from this group and decide if the next group can receive a higher dose of ASP3082. The panel will do this for each group until all groups have received ASP3082 (by itself or together with cetuximab) or until suitable doses have been selected for Part 2.

In Part 2, ASP3082 will be given in by itself, or in combination with the other study treatments.

Study treatments will be given through a vein. This is called an infusion. Each treatment cycle is 21 or 28 days long. They will continue treatment until: they have medical problems from the treatment they can't tolerate; their cancer gets worse; they start other cancer treatment; or they ask to stop treatment.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Geschätzt)

681

Phase

  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

      • Shanghai, China
        • Rekrutierung
        • Shanghai Pulmonary Hospital
    • Beijing Municipality
      • Beijing, Beijing Municipality, China
        • Rekrutierung
        • Beijing Cancer Hospital
    • Shanghai Municipality
      • Xuhui District, Shanghai Municipality, China
        • Rekrutierung
        • Fudan University Shanghai Cancer Center
      • Bordeaux, Frankreich
        • Rekrutierung
        • Site FR33002
      • Lyon, Frankreich
        • Rekrutierung
        • Site FR33001
      • Lyon, Frankreich
        • Rekrutierung
        • Site FR33005
    • Grenobele
      • La Tronche, Grenobele, Frankreich
        • Rekrutierung
        • Site FR33003
    • Île-de-France Region
      • Villejuif, Île-de-France Region, Frankreich
        • Rekrutierung
        • Site FR33004
      • Osaka, Japan
        • Rekrutierung
        • Osaka International Cancer Institute
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan
        • Rekrutierung
        • Aichi Cancer Center
    • Chiba
      • Kashiwa, Chiba, Japan
        • Rekrutierung
        • National Cancer Center Hospital East
    • Ehime
      • Matsuyama, Ehime, Japan
        • Rekrutierung
        • Shikoku Cancer Center
    • Fukuoka
      • Kurume, Fukuoka, Japan
        • Rekrutierung
        • Kurume University Hospital
    • Hokkaido
      • Sapporo, Hokkaido, Japan
        • Rekrutierung
        • Hokkaido University Hospital
    • Kanagawa
      • Yokohama, Kanagawa, Japan
        • Rekrutierung
        • Kanagawa Cancer Center
    • Miyagi
      • Sendai, Miyagi, Japan
        • Rekrutierung
        • Tohoku University Hospital
    • Niigata
      • Niigata, Niigata, Japan
        • Rekrutierung
        • Niigata Cancer Center Hospital
    • Osaka
      • Hirakata, Osaka, Japan
        • Rekrutierung
        • Kansai Medical University Hospital
      • Sayama, Osaka, Japan
        • Rekrutierung
        • Kindai University Hospital
    • Shizuoka
      • Sunto-gun, Shizuoka, Japan
        • Rekrutierung
        • Shizuoka Cancer Center
    • Tokyo
      • Chuo-ku, Tokyo, Japan
        • Beendet
        • National Cancer Center Hospital
      • Koto-ku, Tokyo, Japan
        • Rekrutierung
        • Cancer Institute Hospital of JFCR
    • Yamaguchi
      • Ube, Yamaguchi, Japan
        • Rekrutierung
        • Yamaguchi University Hospital
      • San Juan, Puerto Rico, 00935
        • Rekrutierung
        • PanOncology Trials
      • A Coruña, Spanien
        • Rekrutierung
        • Site ES34009
      • Barcelona, Spanien
        • Rekrutierung
        • Site ES34001
      • Barcelona, Spanien
        • Rekrutierung
        • Site ES34008
      • Barcelona, Spanien
        • Rekrutierung
        • Site ES34005
      • Madrid, Spanien
        • Rekrutierung
        • Site ES34004
      • Madrid, Spanien
        • Rekrutierung
        • Site ES34007
      • Madrid, Spanien
        • Rekrutierung
        • Site ES34006
      • Málaga, Spanien
        • Rekrutierung
        • Site ES34002
      • Seville, Spanien
        • Rekrutierung
        • Site ES34003
      • Valencia, Spanien
        • Rekrutierung
        • Site ES34010
    • Navarre
      • Pamplona, Navarre, Spanien
        • Rekrutierung
        • Site ES34011
      • Seoul, Südkorea
        • Rekrutierung
        • Site KR82006
    • Gyeonggi-do
      • Goyang-si, Gyeonggi-do, Südkorea
        • Rekrutierung
        • Site KR82005
      • Seongnam-si, Gyeonggi-do, Südkorea
        • Rekrutierung
        • Site KR82002
    • North Chungcheong
      • Cheongju-si, North Chungcheong, Südkorea
        • Rekrutierung
        • Site KR82007
    • Seoul
      • Jongno -Gu, Seoul, Südkorea
        • Rekrutierung
        • Site KR82001
      • Seodaemun-gu, Seoul, Südkorea
        • Rekrutierung
        • Site KR82003
      • Songpa-gu, Seoul, Südkorea
        • Rekrutierung
        • Site KR82004
    • California
      • Duarte, California, Vereinigte Staaten, 91010
        • Rekrutierung
        • City of Hope National Medical Center
      • Santa Monica, California, Vereinigte Staaten, 90404
        • Rekrutierung
        • UCLA Santa Monica Hematology Oncology
    • Colorado
      • Denver, Colorado, Vereinigte Staaten, 80218
        • Rekrutierung
        • Denver HealthONE Drug Development Unit
    • Connecticut
      • New Haven, Connecticut, Vereinigte Staaten, 06520-8028
        • Rekrutierung
        • Smilow Cancer Center at Yale New Haven Hospital
    • District of Columbia
      • Washington D.C., District of Columbia, Vereinigte Staaten, 20007
        • Rekrutierung
        • Georgetown University Hospital
    • Florida
      • Gainesville, Florida, Vereinigte Staaten, 32610
        • Rekrutierung
        • University of Florida, Davis Cancer Center
      • Lake Mary, Florida, Vereinigte Staaten, 32746
        • Beendet
        • Florida Cancer Specialist
      • Sarasota, Florida, Vereinigte Staaten, 34232-6422
        • Rekrutierung
        • Florida Cancer Specialists & Research Institute Sarasota
    • Kansas
      • Westwood, Kansas, Vereinigte Staaten, 66205
        • Rekrutierung
        • University of Kansas Medical Center
    • Massachusetts
      • Boston, Massachusetts, Vereinigte Staaten, 02215
        • Rekrutierung
        • Beth Israel Deaconess Medical Center
      • Boston, Massachusetts, Vereinigte Staaten, 02215
        • Rekrutierung
        • Dana Farber Cancer Institute
    • Michigan
      • Ypsilanti, Michigan, Vereinigte Staaten, 48197
        • Rekrutierung
        • Trinity Health Ann Arbor Hospital
    • Missouri
      • St Louis, Missouri, Vereinigte Staaten, 63110
        • Rekrutierung
        • Washington University School of Medicine
    • New Jersey
      • Hackensack, New Jersey, Vereinigte Staaten, 07601
        • Rekrutierung
        • Hackensack University Medical Center
    • New York
      • Buffalo, New York, Vereinigte Staaten, 14263
        • Rekrutierung
        • Roswell Park Cancer Institute
      • New York, New York, Vereinigte Staaten, 10065
        • Rekrutierung
        • Memorial Sloan Kettering Cancer Center
      • New York, New York, Vereinigte Staaten, 10032
        • Beendet
        • Columbia University - Herbert Irving Comprehensive Cancer Center
      • Rochester, New York, Vereinigte Staaten, 14642
        • Rekrutierung
        • University of Rochester Medical Center James P. Wilmot Cancer Center
    • Ohio
      • Cleveland, Ohio, Vereinigte Staaten, 44106
        • Rekrutierung
        • Case Western
      • Maumee, Ohio, Vereinigte Staaten, 43537
        • Rekrutierung
        • Taylor Cancer Research Center
    • Oregon
      • Portland, Oregon, Vereinigte Staaten, 97239
        • Rekrutierung
        • Oregon Health and Science University
    • Tennessee
      • Nashville, Tennessee, Vereinigte Staaten, 37232
        • Rekrutierung
        • Vanderbilt University Medical Center
      • Nashville, Tennessee, Vereinigte Staaten, 37203
        • Beendet
        • SCRI Oncology Partners
    • Texas
      • San Antonio, Texas, Vereinigte Staaten, 78229
        • Rekrutierung
        • NEXT Oncology
    • Virginia
      • Fairfax, Virginia, Vereinigte Staaten, 22031
        • Rekrutierung
        • NEXT Oncology - Virginia Cancer Specialists
    • Wisconsin
      • Madison, Wisconsin, Vereinigte Staaten, 53792
        • Rekrutierung
        • University of Wisconsin Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Participant has locally advanced (unresectable) or metastatic solid tumor malignancy with documented Kirsten rat sarcoma viral oncogene homolog [KRAS] G12D mutation and has received prior standard therapy and the investigator does not see any further clinical benefit from continuing such targeted therapy, or is ineligible to receive standard approved therapies (no limit to the number of prior treatment regimens).

  • For the ASP3082 monotherapy escalation cohorts, participants with solid tumor malignancies are allowed to be enrolled. Participants with other known KRAS G12 mutations will not be eligible for the study

  • For ASP3082 combination therapy with Nab-P+GEM or FOLFIRINOX or NALRIFOX: Participant must have mPDAC that has not been previously treated with chemotherapy. If a participant received (neo)adjuvant therapy, tumor recurrence or disease progression must have occurred at least 6 months after completing the last dose of the (neo)adjuvant therapy.

  • Participant consents to provide tumor specimen in a tissue block or unstained serial slides or a tumor biopsy (core needle biopsy or excision) obtained after the last interventional treatment, but prior to start of study intervention. Participant also consents to provide a sample for tumor biopsy during the treatment period as indicated in the study protocol. If a participant cannot provide a fresh tissue biopsy sample, the site should consult with the sponsor/study medical monitor.

  • Participant has at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.

  • Participant has an ECOG performance status of 0, 1 or 2 for dose escalation, and 0 or 1 for dose expansion.

  • Participant's last dose of prior antineoplastic therapy, including any immunotherapy, was 21 days or 5 half-lives, whichever is shorter, prior to initiation of study intervention administration.

  • Participant has completed any radiotherapy (including stereotactic radiosurgery) at least 14 days prior to the start of study intervention administration. Participants must have recovered from all radiation-related toxicities, not require corticosteroids (NOTE: Physiologic replacement dose of hydrocortisone or its equivalent [defined as up to 30 mg per day of hydrocortisone, 2 mg per day of dexamethasone, or up to 10 mg per day of prednisone] is permitted), and not have active radiation pneumonitis. A 1-week washout is permitted for palliative radiation (<= 2 weeks of radiotherapy) to non-central nervous system disease.

  • Participant's adverse events [AEs] (excluding alopecia) from prior therapy have improved to grade 1 or baseline within 14 days prior to start of study intervention (or prior to staring SoC chemotherapy, for first line (1L) participants receiving Nab-P+GEM FOLFIRINOX or NALIRIFOX.

  • Participant has adequate organ function as indicated by protocol laboratory value parameters (If a participant has received a recent blood transfusion, the laboratory tests must be obtained >= 14 days after any blood transfusion.).

  • Female participant is not pregnant, confirmed by pregnancy test and medical evaluation by interview, and at least 1 of the following conditions apply:

    • Not a woman of childbearing potential (WOCBP).
    • WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 6 months after study intervention administration.
    • EU only: For combination therapy with carboplatin, follow contraception guidelines from the time of informed consent through at least 7 months after the final dose of carboplatin.
    • South Korea only: For combination therapy with oxaliplatin, follow contraception guidelines from the time of informed consent through at least 15 months after the final dose of oxaliplatin. For combination therapy with cisplatin, follow contraception guidelines from the time of informed consent through at least 14 months after the final dose of cisplatin.
  • Female participant must agree not to breastfeed starting at screening and throughout the study period and for 6 months after study intervention administration.

  • Female participant must not donate ova starting at first dose of study intervention and throughout the study period and for 6 months after study intervention administration.

  • Male participant with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and for 3 months after study intervention administration.

  • Male participant must not donate sperm during the treatment period and for 3 months after study intervention administration.

  • South Korea only: For combination therapy with oxaliplatin, follow contraception guidelines from the time of informed consent through at least 12 months after the final dose of oxaliplatin. For combination therapy with cisplatin, follow contraception guidelines from the time of informed consent through at least 11 months after the final dose of cisplatin.

  • Male participant with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 3 months after study intervention administration.

  • Participant agrees not to participate in another interventional study while receiving study intervention (Participants who are currently in the follow-up period of an interventional clinical trial are allowed).

  • For ASP3082 Combination Therapy with Pembrolizumab (Cohort G), or Platinum-based Chemotherapy + Pemetrexed +/- Pembrolizumab (Cohort H): Participant must have pathologically documented locally advanced or metastatic (unresectable Stage IIIB-IV) non-small cell lung cancer (NSCLC) (Note: for Cohort H only, the tumor must be non-squamous NSCLC) with KRAS G12D mutation and

    • have received prior platinum-containing chemotherapy (safety lead-in only) or
    • have never received systemic therapy (up to 1 cycle of SoC pembrolizumab [defined as one 21-day cycle of 200 mg] in Cohort G and up to 1 cycle of SoC platinum-based chemotherapy ± pembrolizumab [defined as one 21-day cycle of 200 mg] or pembrolizumab [defined as one 21-day cycle of 200 mg] in Cohort H is permitted prior to Screening, provided a 21-day washout occurs before C1D1) for locally advanced or metastatic NSCLC with no oncogenic driver mutations. Participants who received adjuvant or neoadjuvant platinum-based chemotherapy and developed recurrent or metastatic disease more than 12 months after completing therapy may be enrolled.

Exclusion Criteria:

  • Participant has received investigational therapy within 21 days or 5 half-lives, whichever is shorter, prior to start of study intervention.
  • Participant has symptomatic or untreated central nervous system (CNS) metastases. Participants with asymptomatic, treated CNS metastases are eligible.
  • Participant has leptomeningeal disease as a manifestation of the current malignancy.
  • Participant has a prior malignancy active (i.e., requiring treatment or intervention) within the previous 2 years, except for local malignancies that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix or breast, which are allowed.
  • Participant has a known or suspected hypersensitivity to ASP3082 or any components of the formulation used.
  • Participant with active hepatitis B (including acute hepatitis B virus [HBV] or chronic HBV) or hepatitis C virus [HCV] (ribonucleic acid [RNA] detected by qualitative assay). HCV RNA testing is not required in participants with negative HCV antibody testing.
  • Participant has a known history of human immunodeficiency virus [HIV] infection. No HIV testing is required unless mandated by a local health authority.
  • Participant has had a myocardial infarction or unstable angina within 6 months prior to the start of study intervention, left ventricular ejection fraction (LVEF) < 50% as determined by multigated acquisition (MUGA) scan or echocardiogram (ECHO) or currently has an uncontrolled illness including, but not limited to symptomatic congestive heart failure, clinically significant cardiac disease, unstable angina pectoris, cardiac arrhythmia, obligate use of a cardiac pacemaker, or long QT syndrome.
  • Participant has a corrected QT interval (single electrocardiogram [ECG]) using Fridericia's formula (QTcF) > 450 milliseconds (msec) (men) or >470 msec (women) during screening.
  • Participant has received prior treatment with a specific KRAS G12D inhibitor/degrader or pan-RAS inhibitor/degrader targeting KRAS G12D. Participants who received prior treatment with a KRAS G12D inhibitor/degrader are eligible for the ASP3082 combination therapy cohort.
  • Participant has an active infection requiring intravenous antibiotics within 14 days prior to study intervention.
  • Participant is expected to require another form of antineoplastic therapy while on study treatment.
  • Participant has any condition which makes the participant unsuitable for study participation (such as psychiatric illness/social situations that would limit compliance with study requirements).
  • Participant has had major surgery within 4 weeks prior to first dose of study intervention.

For ASP3082 Combination Therapy:

  • Prior discontinuation of cetuximab treatment due to toxicity or intolerance of cetuximab.
  • History of interstitial lung disease requiring systemic steroid treatment. Note that a participant with resolved pulmonary infections or radiation pneumonitis is eligible.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Nicht randomisiert
  • Interventionsmodell: Sequenzielle Zuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: ASP3082 Dose Escalation (Monotherapy Part 1)

Participants will receive ASP3082 in a 21-day cycle.

Intravenous Infusion

Andere Namen:
  • ASP3082
Experimental: ASP3082 Dose Expansion (Monotherapy Part 2)

Participants will receive ASP3082 with dose level(s) selected from dose escalation (part 1) in a 21-day cycle.

Intravenous Infusion

Andere Namen:
  • ASP3082
Experimental: ASP3082 + Cetuximab Dose Escalation (Combination Therapy Part 1)

Participants will receive ASP3082 in a 21-day cycle. Cetuximab will be administered weekly.

Intravenous Infusion

Andere Namen:
  • ASP3082

Intravenous Infusion

Experimental: ASP3082 + Cetuximab Dose Expansion (Combination Therapy Part 2)

Participants will receive ASP3082 or ASP3082 + Cetuximab with dose level(s) selected from dose escalation (part 1) in a 21-day cycle. Cetuximab will be administered weekly.

Intravenous Infusion

Andere Namen:
  • ASP3082

Intravenous Infusion

Experimental: ASP3082 China Safety Cohort

Participants will receive ASP3082 with dose level selected from dose escalation (Monotherapy part 1) in a 21-day cycle.

Intravenous Infusion

Andere Namen:
  • ASP3082
Experimental: Treatment naive PDAC cohort ASP3082 + FOLFIRINOX

Upon completion of dose escalation (part 1), participants with KRAS G12D mutant will receive ASP3082 in combination with FOLFIRINOX (leucovorin [LV]/fluorouracil [5-FU]/irinotecan/oxaliplatin) with dose level(s) selected from dose escalation (part 1) in a 28-day cycle.

Intravenous Infusion

Andere Namen:
  • ASP3082

Intravenous Infusion

Intravenous Infusion

Intravenous Infusion

Intravenous Infusion

Experimental: Treatment naive PDAC cohort ASP3082 + Nab-Paclitaxel + Gemcitabine

Upon completion of dose escalation (part 1), participants with KRAS G12D mutant will receive ASP3082 in combination with Nab-P + GEM (nanoparticle albumin-bound-paclitaxel plus gemcitabine) with dose level(s) selected from dose escalation (part 1) in a 28-day cycle.

Intravenous Infusion

Andere Namen:
  • ASP3082

Intravenous Infusion

Intravenous Infusion

Experimental: ASP3082 + Docetaxel - NSCLC

Participants with KRAS G12D mutant will receive ASP3082 in combination with docetaxel in a 21-day cycle.

Intravenous Infusion

Andere Namen:
  • ASP3082

Intravenous Infusion

Experimental: ASP3082 + Pembrolizumab - NSCLC

Participants with KRAS G12D mutant will receive ASP3082 in combination with pembrolizumab in a 21-day cycle.

Intravenous Infusion

Andere Namen:
  • ASP3082

Intravenous Infusion

Experimental: ASP3082 + (Cisplatin or Carboplatin) and Pemetrexed +/- Pembrolizumab - NSCLC

Participants with KRAS G12D mutant will receive ASP3082 in combination with platinum-based chemotherapy (cisplatin or carboplatin) and pemetrexed, with or without pembrolizumab in a 21-day cycle.

Intravenous Infusion

Andere Namen:
  • ASP3082

Intravenous Infusion

Intravenous Infusion

Intravenous Infusion

Intravenous Infusion

Experimental: Treatment naive PDAC cohort ASP3082 + NALIRIFOX

Upon completion of dose escalation (part 1), participants with KRAS G12D mutant will receive ASP3082 in combination with NALIRIFOX (leucovorin[LV]/fluorouracil[5-FU]/liposomal irinotecan/oxaliplatin) with dose level(s) selected from dose escalation (part 1) in a 28-day cycle.

Intravenous Infusion

Andere Namen:
  • ASP3082

Intravenous Infusion

Intravenous Infusion

Intravenous Infusion

Intravenous Infusion

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Incidence of Dose Limiting Toxicities (DLTs)
Zeitfenster: Up to 28 Days

A DLT is defined as any event meeting the DLT criteria excluding toxicities clearly related to disease progression or intercurrent illness or standard of care (SoC) regimens as determined by the investigator.

Up to 28 Days
Number of Participants with Adverse Events (AEs)
Zeitfenster: Up to 48 months

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study IP, whether or not considered related to the study investigational product (IP).

Note: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of study IP. This includes events related to the comparator and events related to the (study) procedures.

Up to 48 months
Number of Participants with Serious Adverse Events (SAEs)
Zeitfenster: Up to 48 months

An SAE is defined as any untoward medical occurrence that, at any dose: Results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and other medically important events.

Up to 48 months
Number of Participants with laboratory value abnormalities and/or adverse events (AEs)
Zeitfenster: Up to 48 months

Number of participants with potentially clinically significant laboratory values.

Up to 48 months
Number of Participants with electrocardiogram (ECG) abnormalities and/or adverse events (AEs)
Zeitfenster: Up to 48 months

Number of participants with potentially clinically significant ECG values.

Up to 48 months
Number of Participants with vital sign abnormalities and/or adverse events (AEs)
Zeitfenster: Up to 48 months

Number of participants with potentially clinically significant vital sign values.

Up to 48 months
Number of Participants with physical exam abnormalities and/or adverse events
Zeitfenster: Up to 48 months

Number of participants with potentially clinically significant physical exam values.

Up to 48 months
Number of Participants with Eastern Cooperative Oncology Group (ECOG) performance status
Zeitfenster: Up to 48 months

The ECOG scale will be used to assess performance status. Grades range from 0 (fully active) to 5 (dead). Negative change scores indicate an improvement. Positive scores indicate a decline in performance.

Up to 48 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Zeitfenster: Up to 48 months

ORR is defined as the proportion of participants whose best overall response is rated as complete response (CR) or partial response (PR) per RECIST v1.1.

Up to 48 months
Duration of Response (DOR) per RECIST v 1.1
Zeitfenster: Up to 48 months

DOR is measured from the time measurement criteria are first met for CR/PR (whichever is first recorded) until the first date of documented radiological disease progression per RECIST v1.1 or death in the absence of progression.

Up to 48 months
Disease Control Rate (DCR) per RECIST v 1.1
Zeitfenster: Up to 48 months

DCR is defined as the proportion of participants whose best overall response is rated as CR, PR or SD based on RECIST v1.1.

Up to 48 months
Pharmacokinetics (PK) of ASP3082 in plasma: Area under the concentration-time curve (AUC)
Zeitfenster: Up to 48 months

AUC will be recorded from the PK plasma samples collected.

Up to 48 months
PK of ASP3082 in plasma: Maximum Concentration (Cmax)
Zeitfenster: Up to 48 months

Cmax will be recorded from the PK plasma samples collected.

Up to 48 months
PK of ASP3082 in plasma: concentration immediately prior to dosing at multiple dosing (Ctrough)
Zeitfenster: Up to 48 months

Ctrough will be recorded from the PK plasma samples collected.

Up to 48 months
PK of ASP3082 in plasma: Time of maximum concentration (tmax)
Zeitfenster: Up to 48 months

tmax will be recorded from the PK plasma samples collected.

Up to 48 months
Changes in Kirsten rat sarcoma (KRAS) viral oncogene homolog G12D in tumor samples
Zeitfenster: Up to 48 months

Changes in KRAS G12D in tumor samples will be measured.

Up to 48 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienleiter: Medical Director, Astellas Pharma Inc

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

8. Juni 2022

Primärer Abschluss (Geschätzt)

31. Dezember 2028

Studienabschluss (Geschätzt)

31. Dezember 2028

Studienanmeldedaten

Zuerst eingereicht

16. Mai 2022

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

16. Mai 2022

Zuerst gepostet (Tatsächlich)

19. Mai 2022

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

14. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

13. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 3082-CL-0101
  • jRCT2031220738 (Registrierungskennung: jRCT)
  • CTR20250465 (Registrierungskennung: chinaDrugTrials.org.cn)
  • 2022-501590-39-00 (Registrierungskennung: CTIS (EU))

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

IPD-Sharing-Zeitrahmen

Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

IPD-Sharing-Zugriffskriterien

Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT
  • CSR

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .